SCHEMBL6344424

SCHEMBL6344424

CC(C)S(=O)(=O)NC1CCCCC1(O)c1ccc(OCCNS(C)(=O)=O)cc1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
HTT P42858 1/20 0.39
PKM P14618 2/20 0.36
KDM4E B2RXH2 3/20 0.36
MAPT P10636 1/20 0.36
HRH3 Q9Y5N1 1/20 0.34
TSHR P16473 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
SLC6A9 P48067 1/20 0.33
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6345477 0.97 ALDH1A1 (0.41) ALDH1A1MEN1KMT2AHTTPKM
SCHEMBL6349722 0.94 KDM4E (0.37) ALDH1A1MEN1KMT2AHTTKDM4E
SCHEMBL6348951 0.91 HRH3 (0.35) ALDH1A1MEN1KMT2AHTTKDM4E
SCHEMBL6345788 0.87 MTNR1A (0.43) ALDH1A1MEN1KMT2APKMKDM4E
SCHEMBL6356775 0.87 ALDH1A1 (0.36) ALDH1A1MEN1KMT2AKDM4EHRH3
SCHEMBL6342761 0.86 ALDH1A1 (0.42) ALDH1A1MEN1KMT2AHTTPKM
SCHEMBL6344428 0.85 ALDH1A1 (0.42) ALDH1A1MEN1KMT2AHTTPKM
SCHEMBL6355737 0.84 MTNR1A (0.44) ALDH1A1MEN1KMT2APKMKDM4E
SCHEMBL6345330 0.84 MEN1 (0.37) ALDH1A1MEN1KMT2AKDM4EHRH3
SCHEMBL6354373 0.83 ALDH1A1 (0.43) ALDH1A1MEN1KMT2AHTTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US claimed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US claimed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP claimed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO claimed
US-6900353-B2 Cyclopentyl sulfonamide derivatives ELI LILLY AND COMPANY (US) 2005-05-31 US disclosed
US-20040067984-A1 Cyclopentyl sulfonamide derivatives CANTRELL BUDDY EUGENE (US) 2004-04-08 US disclosed
EP-1334087-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2003-08-13 EP disclosed
WO-2002032858-A1 CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067984-A1 Cyclopentyl sulfonamide derivatives GRIN2A, GRIN1, GRIK5 ALDH1A1 642/4885MEN1 4591/4885KMT2A 2076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.